Madrigal Grants Equity Awards to Seven New Employees
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has granted equity awards to seven new non-executive employees as inducement awards under its 2025 Inducement Plan. These awards, consisting of 1,739 time-based restricted stock units, will vest in four equal annual installments, contingent on continued employment. The grants were made to attract and incentivize the new hires at the biopharmaceutical company, which focuses on developing treatments for a liver disease called metabolic dysfunction-associated steatohepatitis.
MAR 4·Simply Wall St▲
Madrigal Revenue Beats Highlight Rezdiffra Momentum And Investor Trade Offs
Madrigal Pharmaceuticals reported strong Q4 revenue driven by its new MASH therapy, Rezdiffra, which surpassed expectations and gained analyst confidence. Despite still operating at a loss due to high commercialization costs, the early traction of Rezdiffra and analyst optimism suggest a credible path to scaling the franchise. Investors should monitor prescription trends, payer coverage, and operating expenses, acknowledging risks from rising discounts and competition from GLP-1 therapies.
MAR 3·MarketBeat→
Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Mardi Dier Sells 1,183 Shares
Madrigal Pharmaceuticals' CFO Mardi Dier recently sold 1,183 shares of the company's stock for over $505,000, reducing her total holdings by 11.33%. This follows a larger sale in December. The biopharmaceutical company's stock traded up slightly despite missing EPS estimates but beating revenue expectations in its latest quarterly report.
